Central-acting. Works on the brain, not blood flow. Melanocortin receptor agonist for when PDE5 inhibitors aren't enough or aren't appropriate. The peptide approach to desire.
PT-141 (bremelanotide) is a melanocortin-4 agonist activating central desire and arousal circuits, independent of vasodilation. SubQ dosing is 0.75–1.75mg, injected 45–60 min before sexual activity; max 1 dose per 24 hours. Contraindicated in uncontrolled hypertension, CAD, and during concurrent PDE5 inhibitor use.
| Parameter | Details | Contraindications |
|---|---|---|
| Standard dose | 0.75 mg SubQ initial; can increase to 1.25–1.75 mg if needed | Hepatic/renal impairment: reduce dose |
| Timing | Inject SubQ 45–60 min before desired sexual activity | Do NOT combine with sildenafil/tadalafil |
| Frequency | Max 1 dose per 24 hours; no chronic daily dosing | Uncontrolled hypertension, CAD, MI history |
| Monitoring | Baseline BP (must be <180/110); check HR response | Pregnancy, breastfeeding, melanoma history |
PT-141 represents a fundamentally different approach to sexual function. Rather than targeting blood vessels, it activates desire circuits in the brain. It's the first melanocortin agonist approved for sexual dysfunction, opening new possibilities when traditional approaches aren't effective.
PT-141 (bremelanotide) has rapid subcutaneous absorption with quick onset to peak effects. Understanding these parameters optimizes timing and expectations for sexual activity.
| Bioavailability | ~100% (subcutaneous injection) |
| Tmax (time to peak) | ~1 hour |
| Peak plasma concentration | ~15–20 ng/mL (1.75mg dose) |
| Elimination half-life | ~2.7 hours |
| Steady state | Not applicable (acute dosing, as-needed) |
| Volume of distribution | ~40 L (widespread tissue penetration) |
| Protein binding | ~21% (minimal plasma protein binding) |
| Metabolism | Enzymatic hydrolysis (NOT CYP-mediated — minimal drug interactions) |
| Active metabolites | Cleaved to amino acid fragments; inactive |
| Excretion | Renal (~65%); fecal elimination via metabolites |
| Onset of action | 25–45 minutes post-injection for desired effects |
| Duration of action | ~3–4 hours peak effect; ~8 hours detectable |
PT-141 is an as-needed agent (not daily maintenance). Dosing is precisely timed before anticipated sexual activity. Your specialist will determine the final dosing schedule based on assessment.
PT-141 is the first central-acting agent FDA-approved for sexual dysfunction. Below are key clinical trials supporting its use in female sexual interest/arousal disorder (FSIAD) and across genders.
PT-141's side effect profile is favorable for an as-needed agent. Most adverse events are transient (resolving within 4–6 hours). Incidence rates below are from pivotal Phase 3 trials.
PT-141 undergoes enzymatic hydrolysis (NOT CYP-mediated), resulting in minimal drug-drug interactions compared to most pharmaceuticals. Key considerations below:
Book a specialist consultation to discuss whether PT-141 is the right approach for you.